The post hoc analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [75]
Obesity-related comorbidities such as cardiovascular disease: as obesity and metabolic dysfunction worsen, effects of GIP/dual incretin therapies may address risk factors
Now I can kick breaststroke every day
At Integrative Health Miami, peptide therapy for healing and recovery is not a stand-alone quick fix
Qsymia side effects The most common side effects reported in clinical trials include: Paresthesia (tingling or numbness, especially in hands and feet), reported by up to 20% of users at the top dose Dizziness Dysgeusia (altered taste, things taste metallic or strange) Insomnia (due to the stimulant properties of phentermine) Constipation Dry mouth But Qsymia carries several serious warnings that set it apart from GLP-1 medications: Birth defects
